Trial Profile
Pharmacokinetic, pharmacogenetic aspects on drug-drug interactions between rifampicin and efavirenz.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Oct 2018
Price :
$35
*
At a glance
- Drugs Efavirenz (Primary) ; Rifampicin (Primary) ; Antiretrovirals
- Indications HIV infections; Tuberculosis
- Focus Pharmacogenomic; Therapeutic Use
- 14 Mar 2012 Actual initiation date (Jan 2008) added and planned patient number is 800 as reported by Pan-African Clinical Trials Registry record.
- 14 Mar 2012 Planned end date (Jun 2010 ) added as reported by Pan-African Clinical Trials Registry record.
- 17 Sep 2011 New trial record